Protagonist Therapeutics, Inc

(NASDAQ:PTGX)

Latest On Protagonist Therapeutics, Inc (PTGX):

Date/Time Type Description Signal Details
2023-05-26 01:04 ESTNewsProtagonist Therapeutics Sees Steady If Bumpy ProgressN/A
2023-05-24 20:54 ESTNewsProtagonist Therapeutics: All Quiet Heading Into An Important H2 2023N/A
2023-05-12 13:28 ESTNewsProtagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseasesN/A
2023-05-05 17:50 ESTNewsProtagonist GAAP EPS of -$0.67 in-lineN/A
2023-04-05 11:14 ESTNewsProtagonist Therapeutics prices $100M offeringN/A
2023-04-04 19:17 ESTNewsProtagonist falls on $100M public offeringN/A
2023-03-16 06:46 ESTNewsProtagonist GAAP EPS of -$0.69 misses by $0.10N/A
2023-03-09 21:16 ESTNewsProtagonist Therapeutics: More Good News Likely To ComeN/A
2023-03-07 23:28 ESTNewsJohnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidateN/A
2023-03-07 08:43 ESTNewsCDTX, PTGX and TAST among premarket gainersN/A
2022-11-08 17:47 ESTNewsProtagonist GAAP EPS of -$0.64 beats by $0.23N/A
2022-08-05 06:50 ESTNewsProtagonist GAAP EPS of -$0.84 beats by $0.10N/A
2022-06-15 13:34 ESTNewsProtagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - SlideshowN/A
2022-06-08 23:40 ESTNewsProtagonist: Too Many Red FlagsN/A
2022-06-01 03:40 ESTNewsProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022N/A
2022-05-05 08:14 ESTNewsProtagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65MN/A
2022-04-26 17:35 ESTNewsProtagonist hits 52-week low as Street reacts to data for ulcerative colitis candidateN/A
2022-04-26 01:38 ESTNewsProtagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitisN/A
2022-04-15 02:54 ESTNewsProtagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertideN/A
2022-03-29 08:38 ESTNewsAsif Ali is the new finance chief at Protagonist TherapeuticsN/A
2022-02-28 17:25 ESTNewsProtagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62MN/A
2022-02-01 13:28 ESTNewsProtagonist Is Still Being Undervalued Like There's Real RiskN/A
2021-12-10 01:25 ESTNewsProtagonist Therapeutics (PTGX) Investor Presentation - SlideshowN/A
2021-12-02 23:48 ESTNewsProtagonist chooses candidate to advance into phase 2 in collaboration with JanssenN/A
2021-11-15 11:02 ESTNewsPhase 2a data supports Protagonist genetic liver disease drug rusfertideN/A
2021-10-12 11:34 ESTNewsJ.P. Morgan upgrades Protagonist to overweight following clinical hold removalN/A
2021-10-11 16:22 ESTNewsProtagonist gains nearly double after FDA removes clinical hold on rusfertide programN/A
2021-10-11 16:21 ESTNewsProtagonist price target raised at Northland following removal of clinical holdN/A
2021-10-06 15:26 ESTNewsPTGX is at high risk of performing badlyN/A
2021-09-30 21:08 ESTNewsProtagonist Therapeutics: How To Buy The DipN/A
2021-09-28 00:11 ESTNewsWarning: PTGX has been downgraded to Very BearishN/A
2021-09-25 08:13 ESTNewsBELLUS Health, Akoya Biosciences lead weekly healthcare gainers; Protagonist trailN/A
2021-09-22 04:02 ESTNewsProtagonist loses more than half after FDA placed clinical hold on rusfertide studiesN/A
2021-09-22 04:01 ESTNewsBELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trailN/A
2021-09-22 04:00 ESTNewsProtagonist extends slide as regulatory setback prompts downgrade at JP MorganN/A
2021-09-22 03:59 ESTNewsWarning: PTGX has been downgraded to Very Bearish.N/A
2021-08-10 10:13 ESTNewsProtagonist Therapeutics resolves contract dispute with Zealand PharmaN/A
2021-07-21 20:41 ESTNewsDosing underway in Protagonist Therapeutics' early-stage study of PN-232N/A
2021-07-21 20:32 ESTNewsProtagonist wins FDA Breakthrough Therapy Designation for blood cancer therapyN/A
2021-07-21 20:24 ESTNewsProtagonist climbs on positive effect in mid-stage study for rusfertide in polycythemia veraN/A
2021-07-21 20:23 ESTNewsBiogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst actionN/A
2021-07-21 20:22 ESTNewsProtagonist Therapeutics slumps 7.5% on raising $100M via public offeringN/A
2021-07-21 20:22 ESTNewsRAPT, SIOX, ACHL and PTGX among after-hours moversN/A
2021-07-21 20:21 ESTNewsProtagonist Therapeutics secures $115M capital via equity raiseN/A
2021-07-21 20:16 ESTNewsProtagonist Therapeutics closes $132M capital raiseN/A
2021-05-05 01:39 ESTNewsProtagonist EPS beats by $0.03, beats on revenueN/A
2021-03-12 04:31 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 04:31 ESTAnalyst RatingThe Analyst Target Price has increased from $35.4 to $37.Buy
2021-03-11 12:47 ESTNewsProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 04:23 ESTEarnings EstimateAn EPS average of -$1.48 is estimated for the 2022 year.Sell

About Protagonist Therapeutics, Inc (PTGX):

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Quotes by TradingView

See Advanced Chart

General

  • Name Protagonist Therapeutics, Inc
  • Symbol PTGX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2016-08-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.protagonist-inc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 37.31
  • Price/Book (Most Recent Quarter) 4.86
  • Enterprise Value Revenue 37.04
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.97
  • Next Year EPS Estimate -$2.12
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -231%
  • Operating Margin -225%
  • Return on Assets -17%
  • Return on Equity -37%
  • Revenue 28.63 million
  • Earnings Per Share -$2.74
  • Revenue Per Share $0.83
  • Gross Profit 28.63 million
  • Quarterly Earnings Growth 107.8%
View More

Highlights

  • Market Capitalization 1.36 billion
  • EBITDA -70271000
  • Analyst Target Price $37
  • Book Value Per Share $6.39
View More

Share Statistics

  • Shares Outstanding 43.81 million
  • Shares Float 27.88 million
  • % Held by Insiders 161%
  • % Held by Institutions 93.65%
  • Shares Short 2.77 million
  • Shares Short Prior Month 2.78 million
  • Short Ratio 8.34
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.55
  • 52 Week High $31.58
  • 52 Week Low $5.44
  • 50 Day Moving Average 26.03
  • 200 Day Moving Average 22.63
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Protagonist Therapeutics, Inc (PTGX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$5.65 million-$0.48-$0.48-0.61%
2020-09-302020-11-04$N/A-$0.21-$0.6165.71%
2020-06-302020-08-06$N/A-$0.59-$0.57-2.91%
2020-03-312020-05-07$3.65 million-$0.72-$0.69-4.05%
2019-12-312020-03-10$2.72 million-$0.63-$0.652.78%
2019-09-302019-11-06$4.14 million-$0.61-$0.7720.26%
2019-06-302019-08-07$-8189000-$1.18-$0.39-206.49%
2019-03-312019-05-08$1.56 million-$0.58-$0.56-4.5%
2018-12-312019-03-12$2.35 million-$0.57-$0.47-20.25%
2018-09-302018-11-06$6.12 million-$0.38-$0.37-1.79%
2018-06-302018-08-07$11.67 million-$0.41-$0.30-35.18%
2018-03-312018-05-09$10.78 million-$0.36-$0.24-50%
2017-12-312018-03-07$11.28 million-$0.15-$0.3455.88%
2017-09-302017-11-06$8.78 million-$0.29-$0.8163.98%
2017-06-302017-08-08$N/A-$0.89-$0.86-4.09%
2017-03-312017-05-10$N/A-$0.84-$0.67-26.32%
2016-12-312017-03-07$N/A-$0.67-$0.52-28.85%
2016-09-302016-11-14$N/A-$0.87-$0.64-35.94%
2016-06-302016-07-11$N/A-$40.89-$0.83-4826.51%

Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 19.49 million N/A N/A 18.77 million 15.91 million
Income Before Tax -18.89 million N/A N/A -19.9 million -16.65 million
Selling General Administrative 4.99 million N/A N/A 4.58 million 4.11 million
Gross Profit N/A N/A N/A N/A 2.72 million
Ebit -18.76 million N/A N/A -19 million -17.3 million
Operating Income -18.83 million N/A N/A -19.7 million -17.3 million
Income Tax Expense N/A N/A 1.13 million 176000 856000
Total Revenue 5.65 million N/A N/A 3.65 million 2.72 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net -9000 N/A N/A -490000 654000
Net Income From Continuing Operations -18.89 million N/A N/A -20.08 million -17.5 million
Net Income Applicable to Common Shares -18.89 million -7.76 million -19.42 million -20.08 million -17.5 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A -32.35 million
Change to Liabilities -13.18 million -5.87 million -1.57 million N/A -4.06 million
Total Cash Flow from Investing Activities -54.12 million -5.17 million 42.73 million N/A -32.04 million
Net Borrowings N/A -10.52 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A 25.24 million
Change to Operating Activities 1.85 million -590000 -679000 N/A 725000
Change in Cash N/A N/A N/A N/A -20.95 million
Total Cash from Operating Activities -16.29 million -21.48 million -15.85 million N/A -14.25 million
Depreciation N/A N/A N/A N/A 639000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 2.94 million
Other Cash Flow from Financing Activities N/A -7000 -7000 N/A N/A
Change to Net Income 1.97 million 3.18 million 2.62 million N/A 1.91 million
Capital Expenditures N/A N/A N/A N/A -309000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 44.86 million N/A N/A 72.24 million N/A
Total Stockholder Equity 279.61 million N/A N/A 62.67 million N/A
Other Current Liabilities 15.94 million 18.84 million N/A N/A N/A
Total Assets 324.47 million N/A N/A 134.9 million N/A
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 6.29 million 10000 N/A 10000 N/A
Retained Earnings -283.81 million -264.93 million -257.16 million -237.74 million N/A
Other Liabilities 121000 4.28 million 16.88 million 20.42 million N/A
Other Assets 450000 450000 450000 1.53 million N/A
Cash 117.36 million N/A N/A 60.22 million N/A
Total Current Liabilities 40.24 million 38.56 million N/A 36.37 million N/A
Other Stockholder Equity 28000 -88000 -208000 107000 N/A
Property, Plant & Equipment 1.46 million 6.69 million 7.06 million 7.38 million N/A
Total Current Assets 315.61 million 204.15 million N/A 125.99 million N/A
Long Term Investments 2 million N/A N/A N/A N/A
Net Tangible Assets 279.61 million 169.59 million 167.49 million 62.67 million N/A
Short Term Investments 188.45 million N/A N/A 57.3 million N/A
Long Term Debt N/A N/A N/A 9.83 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 24.31 million 2.8 million N/A 3.7 million N/A

Protagonist Therapeutics, Inc (PTGX) Chart:

Protagonist Therapeutics, Inc (PTGX) News:

Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protagonist Therapeutics, Inc (PTGX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-05-163013CALL0 178.53TRUE00
2025-05-16358CALL0 17251.52TRUE00
2025-05-16405.95CALL0 1143.59TRUE00
2025-05-16453.43CALL2 2756.49TRUE3.430
2025-05-16501.6CALL0 50853.18FALSE00
2025-05-16550.5CALL0 100161.22FALSE00
2025-05-16600CALL0 0110.79FALSE00
2025-05-16650CALL0 0143.11FALSE00
2025-05-16700CALL0 0159.2FALSE00
2025-05-16750CALL0 0173.51FALSE00
2025-05-16800CALL0 0186.42FALSE00
2025-05-16300.85PUT0 3103.96FALSE00
2025-05-16350PUT0 091.19FALSE00
2025-05-16403.1PUT0 1560.08FALSE00
2025-05-16452.44PUT0 2859.82FALSE00
2025-05-16505PUT0 5659.06TRUE00
2025-05-16550PUT0 059.58TRUE00
2025-05-16600PUT0 064.92TRUE00
2025-05-16650PUT0 075.98TRUE00
2025-05-16700PUT0 079.4TRUE00
2025-05-16750PUT0 095.32TRUE00
2025-05-16800PUT0 0113.56TRUE00
2025-07-182033CALL0 20143.77TRUE00
2025-07-1822.515.44CALL0 80125.87TRUE00
2025-07-182515.99CALL0 8068.8TRUE00
2025-07-183012.7CALL0 1659.76TRUE00
2025-07-183525CALL0 1056.35TRUE00
2025-07-18407.1CALL0 3650.67TRUE00
2025-07-18454.98CALL0 6252.68TRUE00
2025-07-18503CALL5 7448.07FALSE30
2025-07-18551.95CALL0 1851.59FALSE00
2025-07-18600.61CALL0 107353.35FALSE00
2025-07-18650.54CALL0 126855.41FALSE00
2025-07-18703.6CALL0 670.42FALSE00
2025-07-18750.34CALL0 497.69FALSE00
2025-07-18800CALL0 0105.04FALSE00
2025-07-18850CALL0 0111.74FALSE00
2025-07-18200PUT0 0179.37FALSE00
2025-07-1822.51.25PUT0 3147.09FALSE00
2025-07-18251.65PUT0 1140.53FALSE00
2025-07-18301.1PUT0 26979.65FALSE00
2025-07-18351PUT0 172364.54FALSE00
2025-07-18403.8PUT0 3649.95FALSE00
2025-07-18454.7PUT0 102152.2FALSE00
2025-07-18505.5PUT0 2253.34TRUE00
2025-07-18558.5PUT0 2552.91TRUE00
2025-07-186013.2PUT0 1050.13TRUE00
2025-07-186522.51PUT0 157.77TRUE00
2025-07-187022PUT0 154.81TRUE00
2025-07-18750PUT0 065.58TRUE00
2025-07-188033.3PUT0 076.85TRUE00
2025-07-18850PUT0 076.3TRUE00
2025-10-172016.5CALL0 4471.04TRUE00
2025-10-1722.531CALL0 157.04TRUE00
2025-10-17250CALL0 064.03TRUE00
2025-10-17300CALL0 062.31TRUE00
2025-10-17350CALL0 057.77TRUE00
2025-10-174010.4CALL0 159.49TRUE00
2025-10-174512.9CALL0 354.91TRUE00
2025-10-17505.4CALL0 959.91FALSE00
2025-10-17554.4CALL0 2455.53FALSE00
2025-10-17603.3CALL0 2051.94FALSE00
2025-10-17657.2CALL0 756.65FALSE00
2025-10-17701.6CALL0 359.54FALSE00
2025-10-17752.35CALL0 264.48FALSE00
2025-10-17800CALL0 056.56FALSE00
2025-10-17853.35CALL0 158.47FALSE00
2025-10-17200PUT0 0128.67FALSE00
2025-10-1722.50PUT0 075.88FALSE00
2025-10-17250PUT0 088.14FALSE00
2025-10-17305PUT0 4478.05FALSE00
2025-10-17351.65PUT0 261.04FALSE00
2025-10-17405.1PUT0 1955.78FALSE00
2025-10-17455.4PUT0 1558.64FALSE00
2025-10-17505.9PUT0 3060.45TRUE00
2025-10-175510.6PUT0 10455.96TRUE00
2025-10-176013PUT0 256.19TRUE00
2025-10-17650PUT0 051.6TRUE00
2025-10-17700PUT0 057.19TRUE00
2025-10-17750PUT0 055.35TRUE00
2025-10-17800PUT0 062.29TRUE00
2025-10-178527.4PUT0 064.53TRUE00

Latest PTGX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST13$7.08
Jun 13, 2022 7:59 PM EST8$7.07
Jun 13, 2022 7:59 PM EST1$7.07
Jun 13, 2022 7:59 PM EST14$7.07
Jun 13, 2022 7:59 PM EST34$7.09

Protagonist Therapeutics, Inc (PTGX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2018-09-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000018029279/0000000000-18-029279-index.htm
2019-11-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000019015720/0000000000-19-015720-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506619001298/0000315066-19-001298-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506620001141/0000315066-20-001141-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720008027/0000834237-20-008027-index.htm
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266419000928/0000902664-19-000928-index.htm
2020-05-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266420002197/0000902664-20-002197-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189518002281/0000921895-18-002281-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189519000465/0000921895-19-000465-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189520000521/0000921895-20-000521-index.htm
2018-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041318002140/0000930413-18-002140-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041319000575/0000930413-19-000575-index.htm
2018-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918005447/0001047469-18-005447-index.htm
2018-09-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/0001047469-18-006015-index.htm
2018-09-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918006444/0001047469-18-006444-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746919002642/0001047469-19-002642-index.htm
2019-10-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746919006014/0001047469-19-006014-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746919006551/0001047469-19-006551-index.htm
2020-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746920002368/0001047469-20-002368-index.htm
2020-05-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920002943/0001047469-20-002943-index.htm
2020-05-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920003025/0001047469-20-003025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049635/0001104659-18-049635-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/0001104659-18-049963-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465918057889/0001104659-18-057889-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918063178/0001104659-18-063178-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918066340/0001104659-18-066340-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918070107/0001104659-18-070107-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/0001104659-18-075322-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014250/0001104659-19-014250-index.htm
2019-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014317/0001104659-19-014317-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919017130/0001104659-19-017130-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465919024116/0001104659-19-024116-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027659/0001104659-19-027659-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027662/0001104659-19-027662-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919029003/0001104659-19-029003-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/0001104659-19-032445-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035338/0001104659-19-035338-index.htm
2019-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035942/0001104659-19-035942-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919044426/0001104659-19-044426-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919058437/0001104659-19-058437-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919060537/0001104659-19-060537-index.htm
2019-11-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465919065981/0001104659-19-065981-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/0001104659-19-068332-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919069217/0001104659-19-069217-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920021728/0001104659-20-021728-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/0001104659-20-024253-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031381/0001104659-20-031381-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031453/0001104659-20-031453-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920035420/0001104659-20-035420-index.htm
2020-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465920047714/0001104659-20-047714-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920058140/0001104659-20-058140-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920059922/0001104659-20-059922-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920067747/0001104659-20-067747-index.htm
2020-06-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1377121/000110465920070830/0001104659-20-070830-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920091424/0001104659-20-091424-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920094719/0001104659-20-094719-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920104437/0001104659-20-104437-index.htm
2020-10-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920111763/0001104659-20-111763-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920121408/0001104659-20-121408-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312518345594/0001193125-18-345594-index.htm
2019-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519015661/0001193125-19-015661-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519028285/0001193125-19-028285-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519040996/0001193125-19-040996-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312520038117/0001193125-20-038117-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037316/0001209191-18-037316-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/0001209191-18-037317-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/0001209191-18-037318-index.htm
2018-07-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118042575/0001209191-18-042575-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003141/0001209191-19-003141-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-01-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003645/0001209191-19-003645-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/0001209191-19-003994-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022776/0001209191-19-022776-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/0001209191-19-030616-index.htm
2019-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034081/0001209191-19-034081-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034082/0001209191-19-034082-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036195/0001209191-19-036195-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036203/0001209191-19-036203-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036204/0001209191-19-036204-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036207/0001209191-19-036207-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/0001209191-19-036211-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/0001209191-19-036214-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/0001209191-20-014088-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014090/0001209191-20-014090-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/0001209191-20-014092-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014097/0001209191-20-014097-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/0001209191-20-014100-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120023949/0001209191-20-023949-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120026593/0001209191-20-026593-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033016/0001209191-20-033016-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033020/0001209191-20-033020-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033022/0001209191-20-033022-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033026/0001209191-20-033026-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/0001209191-20-033031-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/0001209191-20-033032-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2020-08-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047233/0001209191-20-047233-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047246/0001209191-20-047246-index.htm
2018-08-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465918005609/0001214659-18-005609-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465919001113/0001214659-19-001113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465920001392/0001214659-20-001392-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000131924419000056/0001319244-19-000056-index.htm
2019-12-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315219019237/0001493152-19-019237-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315220002364/0001493152-20-002364-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000155837018006590/0001558370-18-006590-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/0001558370-18-006639-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018008657/0001558370-18-008657-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837019001853/0001558370-19-001853-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/0001558370-19-004481-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/0001558370-19-007515-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/0001558370-19-010201-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/0001558370-20-002334-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020005785/0001558370-20-005785-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/0001558370-20-009681-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020012597/0001558370-20-012597-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999518002437/9999999995-18-002437-index.htm
2019-11-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999519002648/9999999995-19-002648-index.htm

Protagonist Therapeutics, Inc (PTGX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-11CHAITAN PHD KHOSLADirectorSell2,499.0017.1942,952.060.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy562.005.092,860.581,175.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2020-03-12HAROLD E SELICKDirectorBuy12,000.006.7080,400.0015,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2019-02-28Suneel GuptaEVP Clinical OperationsBuy7,500.0017,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell2,580.007.7119,891.8024,178.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2020-08-11CHAITAN PHD KHOSLADirectorBuy2,499.001.894,723.112,499.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-02-28Samuel R SaksChief Development OfficerBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell198.008.151,613.7026,758.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2018-08-15Richard S. ShamesChief Medical OfficerBuy18,750.0026,956.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-15Thomas P. O'NeilChief Financial OfficerBuy21,100.0030,560.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-03-01Richard S. ShamesChief Medical OfficerSell657.008.035,275.7132,021.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-02-28Richard S. ShamesChief Medical OfficerBuy8,500.0032,678.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-04-01HAROLD E SELICKDirectorBuy3,310.001.314,336.103,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2018-08-15DINESH V PH D PATELPresident and CEOBuy82,050.00345,829.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell10,132.007.7178,117.72357,264.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell777.008.106,292.22367,396.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-01-11DINESH V PH D PATELPresident and CEOBuy22,344.001.1625,919.04368,173.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-02-06David Y LiuChief Scientific OfficerSell3,821.007.7429,561.5537,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-08-06DINESH V PH D PATELPresident and CEOSell10,792.008.8595,535.10374,792.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-11-26DINESH V PH D PATELPresident and CEOBuy4,000.001.164,640.00379,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-03-01DINESH V PH D PATELPresident and CEOSell2,183.008.0317,529.49383,831.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-02-28DINESH V PH D PATELPresident and CEOBuy28,750.00386,014.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy10,000.005.5555,500.00389,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2018-08-15David Y LiuChief Scientific OfficerBuy25,800.0040,828.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy20,000.005.65113,000.00409,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2020-03-12DINESH V PH D PATELPresident and CEOBuy18,344.001.1621,279.04429,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-20DINESH V PH D PATELPresident and CEOBuy10,000.001.8918,900.00439,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2019-12-03Suneel GuptaEVP Clinical OperationsBuy30,000.005.13153,900.0049,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-08-06David Y LiuChief Scientific OfficerSell3,395.008.8530,044.0549,802.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-03-01David Y LiuChief Scientific OfficerSell810.008.036,504.3051,197.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-02-28David Y LiuChief Scientific OfficerBuy15,000.0052,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy613.005.103,126.30613.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03Bryan GiraudoDirectorBuy8,000.005.7045,620.008,000.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm